Bristol-Myers Squibb Co., whose top- selling blood thinner Plavix faces generic competition next year, said fourth-quarter profit decreased 41 percent, missing analyst estimates after one-time tax charges from restructuring.
More...
Toggle signature
||||| Mentor Group Access Now! |||||
More...
Toggle signature
||||| Mentor Group Access Now! |||||